Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 29;14:17459. doi: 10.1038/s41598-024-68338-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Kaplan–Meier curves of (a) PFS and (b) OS of all patients treated with prexasertib with evaluable disease by RECIST (95% confidence interval shaded in gray). Censored patients are denoted by tick marks along the survival curves. Kaplan–Meier curves showing (c) PFS and (d) OS in patients separated by Gynecologic Cancer Intergroup (GCIG) CA125 response or no response. Spider plot of RECIST tumor size change from baseline in (e) patients with GCIG CA125 response and (f) patients with no GCIG CA125 response. CA125 cancer antigen 125, CHK1i cell cycle checkpoint kinase 1 inhibitor, GCIG Gynecologic Cancer InterGroup, HR hazard ratio, MV multivariate, OS overall survival, PFS progression-free survival, RECIST response evaluation criteria in solid tumors, UV univariate.